496 related articles for article (PubMed ID: 19903491)
41. Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies.
Fanen P; Wohlhuter-Haddad A; Hinzpeter A
Int J Biochem Cell Biol; 2014 Jul; 52():94-102. PubMed ID: 24631642
[TBL] [Abstract][Full Text] [Related]
42. Genome Editing for Cystic Fibrosis.
Wang G
Cells; 2023 Jun; 12(12):. PubMed ID: 37371025
[TBL] [Abstract][Full Text] [Related]
43. Cellular heterogeneity of CFTR expression and function in the lung: implications for gene therapy of cystic fibrosis.
Jiang Q; Engelhardt JF
Eur J Hum Genet; 1998 Jan; 6(1):12-31. PubMed ID: 9781011
[TBL] [Abstract][Full Text] [Related]
44. Emerging technologies for cystic fibrosis transmembrane conductance regulator restoration in all people with CF.
Egan ME
Pediatr Pulmonol; 2021 Feb; 56 Suppl 1(Suppl 1):S32-S39. PubMed ID: 32681713
[TBL] [Abstract][Full Text] [Related]
45. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
Lee T; Southern KW
Cochrane Database Syst Rev; 2007 Apr; (2):CD005599. PubMed ID: 17443603
[TBL] [Abstract][Full Text] [Related]
46. Understanding how cystic fibrosis mutations cause a loss of Cl- channel function.
Sheppard DN; Ostedgaard LS
Mol Med Today; 1996 Jul; 2(7):290-7. PubMed ID: 8796909
[TBL] [Abstract][Full Text] [Related]
47. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
Lee TW; Southern KW
Cochrane Database Syst Rev; 2013 Nov; (11):CD005599. PubMed ID: 24282073
[TBL] [Abstract][Full Text] [Related]
48. Current and novel therapeutic strategies for the management of cystic fibrosis.
Gbian DL; Omri A
Expert Opin Drug Deliv; 2021 May; 18(5):535-552. PubMed ID: 33426936
[No Abstract] [Full Text] [Related]
49. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
[TBL] [Abstract][Full Text] [Related]
50. Changing the Paradigm - Treating the Basic Defect in Cystic Fibrosis.
Guglani L
Indian J Pediatr; 2015 Aug; 82(8):727-36. PubMed ID: 26077199
[TBL] [Abstract][Full Text] [Related]
51. Advances in gene therapy for cystic fibrosis lung disease.
Yan Z; McCray PB; Engelhardt JF
Hum Mol Genet; 2019 Oct; 28(R1):R88-R94. PubMed ID: 31332440
[TBL] [Abstract][Full Text] [Related]
52. Genetic therapies for cystic fibrosis lung disease.
Sinn PL; Anthony RM; McCray PB
Hum Mol Genet; 2011 Apr; 20(R1):R79-86. PubMed ID: 21422098
[TBL] [Abstract][Full Text] [Related]
53. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.
Wagner JA; Messner AH; Moran ML; Daifuku R; Kouyama K; Desch JK; Manley S; Norbash AM; Conrad CK; Friborg S; Reynolds T; Guggino WB; Moss RB; Carter BJ; Wine JJ; Flotte TR; Gardner P
Laryngoscope; 1999 Feb; 109(2 Pt 1):266-74. PubMed ID: 10890777
[TBL] [Abstract][Full Text] [Related]
54. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
Cuyx S; De Boeck K
Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
[TBL] [Abstract][Full Text] [Related]
55. Cystic Fibrosis: Pathophysiology of Lung Disease.
Bergeron C; Cantin AM
Semin Respir Crit Care Med; 2019 Dec; 40(6):715-726. PubMed ID: 31659725
[TBL] [Abstract][Full Text] [Related]
56. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
Cho DY; Zhang S; Lazrak A; Grayson JW; Peña Garcia JA; Skinner DF; Lim DJ; Mackey C; Banks C; Matalon S; Woodworth BA
Int Forum Allergy Rhinol; 2019 Jan; 9(1):100-105. PubMed ID: 30152192
[TBL] [Abstract][Full Text] [Related]
57. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life.
Cohen-Cymberknoh M; Shoseyov D; Kerem E
Am J Respir Crit Care Med; 2011 Jun; 183(11):1463-71. PubMed ID: 21330455
[TBL] [Abstract][Full Text] [Related]
58. Repairing the basic defect in cystic fibrosis - one approach is not enough.
Farinha CM; Matos P
FEBS J; 2016 Jan; 283(2):246-64. PubMed ID: 26416076
[TBL] [Abstract][Full Text] [Related]
59. Cystic fibrosis: toward personalized therapies.
Ikpa PT; Bijvelds MJ; de Jonge HR
Int J Biochem Cell Biol; 2014 Jul; 52():192-200. PubMed ID: 24561283
[TBL] [Abstract][Full Text] [Related]
60. Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?
Büscher R; Grasemann H
Naunyn Schmiedebergs Arch Pharmacol; 2006 Nov; 374(2):65-77. PubMed ID: 17033796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
